Tag - SYN

Developments

Synthetic Biologics engages AGP to explore strategic alternatives

Synthetic Biologics (NYSE American:SYN) engaged Alliance Global Partners as an advisor to help the company evaluate strategic alternatives. The company is considering a variety of options, including an acquisition...

November 17, 2020

Developments

Synthetic Biologics discontinues Phase 2b irritable bowel syndrome trial

Synthetic Biologics (NYSE American:SYN) reported disappointing results from an interim futility analysis of its Phase 2b clinical study of SYN-010 for the treatment of irritable bowel syndrome with constipation. While...

October 2, 2020

Markets

Maxim starts Synthetic Biologics at buy; PT $1.50

Maxim Group initiated coverage of Synthetic Biologics (NYSE American:SYN) with a “buy” rating and price target of $1.50. The stock closed at 47 cents on June 17. The company is focused on the gut microbiome with two...

June 18, 2020

Tag - SYN

Synthetic Biologics engages AGP to explore strategic alternatives

Synthetic Biologics discontinues Phase 2b irritable bowel syndrome trial

Maxim starts Synthetic Biologics at buy; PT $1.50

General

More